These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2001454)

  • 1. Protection from arabinofuranosylcytosine and n-mustard-induced myelotoxicity using hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys monomer and dimer.
    Paukovits WR; Moser MH; Binder KA; Paukovits JB
    Blood; 1991 Mar; 77(6):1313-9. PubMed ID: 2001454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of haemoregulatory peptides (pEEDCK monomer and dimer) for reduction of cytostatic drug induced haemopoietic damage.
    Paukovits WR; Moser MH; Binder KA; Paukovits JB
    Cancer Treat Rev; 1990 Sep; 17(2-3):347-54. PubMed ID: 2272050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer: a redox-mediated mechanism for demand-induced hematopoietic regulation.
    Paukovits WR; Paukovits JB; Moser MH; Konstantinov S; Schulte-Hermann R
    Exp Hematol; 1998 Aug; 26(9):851-8. PubMed ID: 9694506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-CFU-S quiescence and stem cell exhaustion after cytostatic drug treatment: protective effects of the inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK).
    Paukovits WR; Moser MH; Paukovits JB
    Blood; 1993 Apr; 81(7):1755-61. PubMed ID: 8461461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemoregulatory peptide pGlu-Glu-Asp-Cys-Lys: a new synthetic derivative for avoiding dimerization and loss of inhibitory activity.
    Paukovits WR; Hergl A; Schulte-Hermann R
    Mol Pharmacol; 1990 Sep; 38(3):401-9. PubMed ID: 2402229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hematotoxic side effects of cytostatic drugs in mice by a synthetic hemoregulatory peptide.
    Paukovits WR; Guigon M; Binder KA; Hergl A; Laerum OD; Schulte-Hermann R
    Cancer Res; 1990 Jan; 50(2):328-32. PubMed ID: 2295072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hematopoietic stem cell proliferation by hemoregulatory peptide pyroGlu-Glu-Asp-Cys-Lys (pEEDCK) provides protection against short-term neutropenia and long-term damage.
    Paukovits WR; Moser MH; Rutter R; Paukovits JB
    Ann N Y Acad Sci; 1991; 628():92-104. PubMed ID: 2069326
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of the hemoregulatory peptide (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 and MIP-1alpha is reduced in bone marrow cultures from patients with chronic myeloid leukemia (CML).
    Karlic H; Louda N; Pfeilstöcker M; Keil F; Lohninger A; Pittermann E; Paukovits J
    Stem Cells; 2001; 19(4):321-8. PubMed ID: 11463952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The hemoregulatory peptide pEEDCK may inhibit stem cell proliferation via hydropathic binding to antisense sequence motifs in interleukin-11 and other growth factors.
    Paukovits JB; Rutter R; Ganglberger E; Karlic HI; Marian B; Paukovits WR
    Mol Pharmacol; 1999 Oct; 56(4):665-74. PubMed ID: 10496948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice.
    Alisauskas RM; Goldenberg DM; Sharkey RM; Blumenthal RD
    Int J Cancer; 1997 Jan; 70(3):323-9. PubMed ID: 9033635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo and in vitro effects of cytokines and the hemoregulatory peptide dimer (pEEDCK)2 (pyroGlu-Glu-Asp-Cys-Lys)2 on G alpha16-positive hematopoiesis.
    Pfeilstöcker M; Karlic H; Paukovits J; Anzenberger G; Louda N; Salamon J; Mühlberger H; Strobl H; Pittermann E; Heinz R
    Leukemia; 1999 Apr; 13(4):590-4. PubMed ID: 10214866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell stimulation in vitro by the dekapeptide (pEEDCK)2: a single-factor alternative for multifactor cocktails.
    Paukovits JB; Paukovits WR
    Leukemia; 1995 Oct; 9 Suppl 1():S48-52. PubMed ID: 7475313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemoprotection against cytostatic drugs by stem cell inhibition.
    Moser MH; Paukovits WR
    Trends Pharmacol Sci; 1991 Aug; 12(8):304-10. PubMed ID: 1949198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo.
    Aidoudi S; Guigon M; Drouet V; Caen JP; Han ZC
    Int J Hematol; 1998 Aug; 68(2):145-55. PubMed ID: 9803673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory peptides in hematopoiesis.
    Guigon M; Bonnet D
    Exp Hematol; 1995 Jun; 23(6):477-81. PubMed ID: 7768302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo modulation of hematopoiesis by a novel hematoregulatory peptide.
    Pelus LM; King AG; Broxmeyer HE; DeMarsh PL; Petteway SR; Bhatnagar PK
    Exp Hematol; 1994 Mar; 22(3):239-47. PubMed ID: 8112423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of a synthetic pentapeptide on hemopoietic stem cells in vitro and in vivo.
    Laerum OD; Paukovits WR
    Exp Hematol; 1984 Jan; 12(1):7-17. PubMed ID: 6230248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect stimulation of hemopoiesis by hemoregulatory peptide (HP5b) dimer in murine long-term bone marrow cultures.
    Veiby OP; Løvhaug D; Fjerdingstad H; Engelsen SJ
    Exp Hematol; 1992 Feb; 20(2):192-5. PubMed ID: 1544388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressive biological activity of a synthetic pentapeptide on highly enriched human and murine marrow hematopoietic progenitors: synergism with recombinant human tumor necrosis factor-alpha and interferon-gamma.
    Lu L; Foa P; Chillemi F; Shen RN; Lin ZH; Carow C; Broxmeyer HE
    Exp Hematol; 1989 Oct; 17(9):935-41. PubMed ID: 2506072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.